Bremelanotide Acetate

Bremelanotide Acetate (CAS No.: 1607799-13-2) is a synthetic melanocortin receptor agonist peptide used as a neuropharmacology and endocrine signaling tool compound in life sciences research, primarily classified within receptor pharmacology and behavior related mechanism studies, with functional relevance to central melanocortin system modulation and downstream neurotransmitter regulation; current evidence supports receptor level activity centered on melanocortin receptor subtypes, including MC4R associated signaling, where agonist engagement is linked to G protein coupled pathway activation and modulation of dopaminergic neurotransmission in preclinical contexts, and reported pharmacological potency for melanocortin agonists of this class is generally characterized within nanomolar to micromolar activity windows depending on assay platform, receptor subtype expression system, and readout modality, while specific response magnitudes can vary across recombinant cell based assays and native tissue models; in biomedical discovery workflows, this molecule is commonly positioned for mechanistic studies of receptor driven behavioral phenotypes, neuroendocrine circuit interrogation, and comparative agonist profiling, with use in in vitro receptor activation assays, pathway biased signaling evaluations, and in vivo animal paradigms that examine motivated or stimulus associated behaviors, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, including species, route of administration, temporal sampling strategy, and endpoint selection.